Effects of Two Fresh Gas Flow Rates During Anesthesia for Lumbar Stabilization Surgery

November 18, 2026 updated by: Hande Gurbuz

Effects of Different Fresh Gas Flow Rates on Respiratory System Mechanics, Postoperative Pulmonary Complications, Sevoflurane Consumption, and Carbon Footprint in Lumbar Stabilization Surgery in Prone Position: A Prospective Randomized Controlled Trial

This study will compare two fresh gas flow rates during general anesthesia in adults undergoing lumbar stabilization surgery while lying face down. Fresh gas flow is the rate at which oxygen and other gases are supplied to the anesthesia breathing system. Lower flow rates may reduce anesthetic use and its environmental impact, but their effects on breathing during prolonged surgery need further evaluation.

Seventy adults will be randomly assigned to receive a fresh gas flow rate of either 0.3 or 2 liters per minute. Both groups will receive sevoflurane anesthesia and standardized mechanical ventilation.

The main outcome is the percentage change in dynamic respiratory system compliance, a measure of how easily the lungs and chest expand during ventilation, between 10 and 120 minutes after reaching the assigned flow rate. Other assessments will include breathing mechanics, blood oxygen and carbon dioxide levels, brain oxygenation, lung ultrasound findings, postoperative oxygen needs, pulmonary complications, and hospital length of stay. Anesthetic and fresh gas consumption, anesthetic cost, and estimated greenhouse gas emissions will also be compared. Fresh gas flow will be increased if predefined safety criteria are met.

Study Overview

Detailed Description

This single-center trial will be conducted at Bursa City Hospital. Adults aged 18 years or older who are scheduled for elective lumbar stabilization surgery in the prone position will be enrolled. Eligible participants will have an American Society of Anesthesiologists physical status classification of I-III, a body mass index below 40 kg/m², and no known pulmonary disease. Written informed consent will be obtained before enrollment. Participants will be assigned by computer-generated randomization to two parallel groups: minimal fresh gas flow at 0.3 L/min or comparator fresh gas flow at 2 L/min.

Before anesthesia induction, demographic characteristics, comorbidities, smoking status, and hemoglobin levels will be recorded. Lung ultrasound will assess 12 zones, with each zone scored from 0 to 3, yielding a total score of 0-36. Higher scores indicate greater loss of lung aeration.

Automated controlled anesthesia will be used to target an end-tidal sevoflurane concentration corresponding to approximately 1 minimum alveolar concentration, with a bispectral index target of 40-60. Volume-controlled ventilation will be standardized.

High fresh gas flow will initially be used after induction and tracheal intubation. After prone positioning and confirmation of hemodynamic and ventilatory stability, the assigned fresh gas flow rate will be applied. Measurements will be obtained at the following time points:

T1: 5-10 minutes after intubation, while supine during the initial high-flow period.

T2: 10 minutes after reaching the assigned fresh gas flow rate in the prone position.

T3: 30 minutes after reaching the assigned flow rate. T4: 60 minutes after reaching the assigned flow rate. T5: 120 minutes after reaching the assigned flow rate.

Respiratory mechanics, hemodynamic variables, cerebral oxygenation, and arterial blood gas measurements will be recorded at the specified intraoperative time points. Dynamic compliance will be calculated as expired tidal volume divided by the difference between peak inspiratory pressure and positive end-expiratory pressure. Its percentage change will be calculated as [(T5 value - T2 value) / T2 value] × 100. Plateau pressure will be measured using an inspiratory hold. Static compliance, driving pressure, airway resistance, elastance, and mechanical power will also be evaluated. Pulmonary gas exchange assessments will include the PaO2/FiO2 ratio, the alveolar-arterial oxygen gradient, and the arterial-to-end-tidal carbon dioxide difference.

At 30 minutes after surgery in the postanesthesia care unit, lung ultrasound, peripheral oxygen saturation, supplemental oxygen requirements, pain, and early pulmonary complications will be assessed. The change in lung ultrasound score will be calculated as the postoperative score minus the preoperative score. Pulmonary complications during hospitalization and hospital length of stay will also be recorded.

Total sevoflurane and fresh gas consumption will be obtained from the anesthesia workstation. Sevoflurane cost will be calculated using the consumed volume and the unit price determined at the end of the study. Estimated sevoflurane-related carbon dioxide equivalent emissions will be calculated using the protocol-specified conversion factor of approximately 0.198 kg CO2e per milliliter of sevoflurane.

Study Type

Interventional

Enrollment (Estimated)

86

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Bursa
      • Bursa, Bursa, Turkey (Türkiye), 16110
        • University of Health Sciences, Bursa City Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age 18 years or older.
  • Scheduled for elective lumbar stabilization surgery in the prone position.
  • American Society of Anesthesiologists (ASA) physical status I-III.
  • Body mass index below 40 kg/m².
  • No known pulmonary disease.
  • Willing and able to provide written informed consent.

Exclusion Criteria:

  • ASA physical status IV or higher.
  • Body mass index of 40 kg/m² or higher.
  • Known pulmonary disease.
  • Declining to participate or not providing written informed consent.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Minimal Fresh Gas Flow (0.3 L/min)

Participants will receive a fresh gas flow rate of 0.3 L/min during sevoflurane anesthesia after prone positioning and confirmation of hemodynamic and ventilatory stability. Mechanical ventilation will follow the standardized study protocol. High fresh gas flow will be used if predefined rescue criteria are met.

Fresh gas flow will be reduced to 0.3 L/min after prone positioning and confirmation of hemodynamic and ventilatory stability. Sevoflurane will be administered using automated controlled anesthesia to target approximately 1 minimum alveolar concentration. The assigned flow will be maintained unless predefined rescue criteria require an increase in fresh gas flow.

Active Comparator: Fresh Gas Flow (2 L/min)

Participants will receive a fresh gas flow rate of 2 L/min during sevoflurane anesthesia after prone positioning and confirmation of hemodynamic and ventilatory stability. Mechanical ventilation will follow the standardized study protocol. High fresh gas flow will be used if predefined rescue criteria are met.

Fresh gas flow will be set at 2 L/min after prone positioning and confirmation of hemodynamic and ventilatory stability. Sevoflurane will be administered using automated controlled anesthesia to target approximately 1 minimum alveolar concentration. The assigned flow will be maintained unless predefined rescue criteria require an increase in fresh gas flow.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage Change in Dynamic Respiratory System Compliance
Time Frame: From 10 to 120 minutes after reaching the assigned fresh gas flow rate in the prone position during surgery.

Dynamic respiratory system compliance (Cdyn), expressed in mL/cmH2O, will be recorded directly from the anesthesia workstation. The percentage change will be calculated as [(Cdyn at T5 - Cdyn at T2) / Cdyn at T2] × 100. T2 is 10 minutes and T5 is 120 minutes after reaching the assigned fresh gas flow rate in the prone position. Negative values indicate a decrease in compliance; higher values indicate better preservation of compliance.

From 10 to 120 minutes after reaching the assigned fresh gas flow rate in the prone position during surgery.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Static Respiratory System Compliance
Time Frame: From 10 to 120 minutes after reaching the assigned fresh gas flow rate in the prone position during surgery.

Static respiratory system compliance (Cstat) will be calculated as expired tidal volume divided by plateau pressure minus positive end-expiratory pressure and expressed in mL/cmH2O. Plateau pressure will be measured during a 2-second inspiratory hold. The change will be calculated as Cstat at T5 minus Cstat at T2. Negative values indicate a decrease in compliance.

From 10 to 120 minutes after reaching the assigned fresh gas flow rate in the prone position during surgery.
Change in Driving Pressure
Time Frame: From 10 to 120 minutes after reaching the assigned fresh gas flow rate in the prone position during surgery.

Driving pressure will be calculated as plateau pressure minus positive end-expiratory pressure and expressed in cmH2O. Plateau pressure will be measured during a 2-second inspiratory hold. The change will be calculated as driving pressure at T5 minus driving pressure at T2. Positive values indicate an increase in driving pressure.

From 10 to 120 minutes after reaching the assigned fresh gas flow rate in the prone position during surgery.
Change in Airway Resistance
Time Frame: From 10 to 120 minutes after reaching the assigned fresh gas flow rate in the prone position during surgery.

Airway resistance will be recorded directly from the anesthesia workstation and expressed in cmH2O·s/L. The change will be calculated as airway resistance at T5 minus airway resistance at T2. Positive values indicate an increase in airway resistance.

From 10 to 120 minutes after reaching the assigned fresh gas flow rate in the prone position during surgery.
Change in Mechanical Power
Time Frame: From 10 to 120 minutes after reaching the assigned fresh gas flow rate in the prone position during surgery.

Mechanical power during volume-controlled ventilation will be calculated as: 0.098 × tidal volume (L) × respiratory rate (breaths/min) × [peak inspiratory pressure - 0.5 × (plateau pressure - positive end-expiratory pressure)]. Pressures will be expressed in cmH2O and mechanical power in J/min. The change will be calculated as mechanical power at T5 minus mechanical power at T2. Positive values indicate an increase in mechanical power.

From 10 to 120 minutes after reaching the assigned fresh gas flow rate in the prone position during surgery.
Change in Respiratory System Elastance
Time Frame: From 10 to 120 minutes after reaching the assigned fresh gas flow rate in the prone position during surgery.

Respiratory system elastance will be recorded directly from the anesthesia workstation. The change will be calculated as elastance at T5 minus elastance at T2. Positive values indicate increased respiratory system stiffness.

From 10 to 120 minutes after reaching the assigned fresh gas flow rate in the prone position during surgery.
Change in PaO2/FiO2 Ratio
Time Frame: From 10 to 120 minutes after reaching the assigned fresh gas flow rate in the prone position during surgery.

The PaO2/FiO2 ratio will be calculated by dividing arterial oxygen partial pressure (PaO2, in mmHg) by the simultaneously recorded inspired oxygen fraction (FiO2, expressed as a decimal). The change will be calculated as the ratio at T5 minus the ratio at T2 and expressed in mmHg. Positive values indicate improved oxygenation.

From 10 to 120 minutes after reaching the assigned fresh gas flow rate in the prone position during surgery.
Total Sevoflurane Consumption
Time Frame: From the start of anesthesia to the end of anesthesia on the day of surgery.

Total liquid sevoflurane consumption during anesthesia will be recorded directly from the anesthesia workstation and expressed in milliliters.

From the start of anesthesia to the end of anesthesia on the day of surgery.
Estimated Sevoflurane-Related Carbon Dioxide Equivalent Emissions
Time Frame: From the start of anesthesia to the end of anesthesia on the day of surgery.

Estimated carbon dioxide equivalent (CO2e) emissions associated with sevoflurane consumption will be calculated by multiplying the total liquid sevoflurane volume consumed during anesthesia by the protocol-specified conversion factor of 0.198 kg CO2e per milliliter. Results will be expressed in kilograms of CO2e. This estimate covers sevoflurane-related emissions rather than the total carbon footprint of anesthesia or surgery.

From the start of anesthesia to the end of anesthesia on the day of surgery.
Change in Lung Ultrasound Score
Time Frame: From before anesthesia induction to 30 minutes after surgery in the postanesthesia care unit.

Lung aeration will be assessed using a 12-zone lung ultrasound examination. Each zone will be scored from 0 to 3, yielding a total score of 0-36, with higher scores indicating greater loss of aeration. The change will be calculated as the postoperative score minus the preoperative score. Positive values indicate worsening lung aeration.

From before anesthesia induction to 30 minutes after surgery in the postanesthesia care unit.
Incidence of Postoperative Pulmonary Complications
Time Frame: Postoperative hospitalization, an average of 10 days.

The proportion of participants experiencing at least one postoperative pulmonary complication during hospitalization will be compared between groups. Complications will include atelectasis, pneumonia, respiratory failure, bronchospasm, aspiration pneumonitis, pleural effusion, and pneumothorax. Each participant will be counted once for the overall incidence, regardless of the number of complications. The type of each complication will also be recorded.

Postoperative hospitalization, an average of 10 days.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Hande Gurbuz, Prof, MD, PhD, University of Health Sciences, Bursa School of Medicine, Bursa City Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

December 1, 2027

Study Completion (Estimated)

December 1, 2027

Study Registration Dates

First Submitted

November 12, 2026

First Submitted That Met QC Criteria

November 18, 2026

First Posted (Actual)

November 19, 2026

Study Record Updates

Last Update Posted (Actual)

November 19, 2026

Last Update Submitted That Met QC Criteria

November 18, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • KAEK-2026-18/2
  • 26-AKD-365 (Other Identifier: Turkish Medicines and Medical Devices Agency (TITCK))

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

There is no plan to share individual participant data with other researchers. Study findings will be reported in aggregate form.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe